Ron Bentsur
Chairman, Chief Executive Officer and President
is a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. We are developing two drug candidates, NXP800 and NXP900:
NXP800 is an oral small molecule that exerts its biologic activity through activation of the kinase GCN2. NXP800 is currently investigated in a clinical trial for the treatment of platinum resistant, ARID1a-mutated ovarian cancer, a development program that was granted Fast Track Designation by the U.S. FDA, and for the treatment of cholangiocarcinoma in an investigator-sponsored clinical trial led by Mayo clinic, an indication that was granted Orphan Drug Designation by the U.S. FDA.
NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900 is currently investigated in a Phase 1 dose escalation clinical trial.
is a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. We are developing two drug candidates, NXP800 and NXP900:
NXP800 is an oral small molecule that exerts its biologic activity through activation of the kinase GCN2. NXP800 is currently investigated in a clinical trial for the treatment of platinum resistant, ARID1a-mutated ovarian cancer, a development program that was granted Fast Track Designation by the U.S. FDA, and for the treatment of cholangiocarcinoma in an investigator-sponsored clinical trial led by Mayo clinic, an indication that was granted Orphan Drug Designation by the U.S. FDA.
NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900 is currently investigated in a Phase 1 dose escalation clinical trial.
Ron Bentsur
Chairman, Chief Executive Officer and President
Enrique Poradosu, PhD
Executive Vice President, Chief Scientific and Business Officer
Shay Shemesh
Executive Vice President, Chief Development and Operations Officer
Ron Bentsur
Chairman, Chief Executive Officer and President
Ken Hoberman
Director
Matthew L. Kaplan
Director
James F. Oliviero, III
Director
Prof. Shannon N. Westin, MD, MPH
Director, Early Drug Development and Phase I Trials
Prof. Gordon B. Mills, MD, PhD
Director of Precision Oncology, Director of SMMART Trials
Prof. Paul Workman, PhD, FRS
Harrap Professor of Pharmacology and Therapeutics